97 related articles for article (PubMed ID: 21187502)
1. Clinical impacts of histological subtyping primary breast cancer.
Fritz P; Klenk S; Goletz S; Gerteis A; Simon W; Brinkmann F; Heidemann E; Lütttgen E; Ott G; Alscher MD; Schwab M; Dippon J
Anticancer Res; 2010 Dec; 30(12):5137-44. PubMed ID: 21187502
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancers: unique clinical presentations and outcomes.
Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].
Wang YJ; Wang N; Wang B; Qin WX; Xue CY
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
6. Implication of laminin and collagen type IV expression in the progression of breast carcinoma.
De Iorio P; Midulla C; Pisani T; Valli C; Grillo L; Di Cocco B; Nofroni I; Vecchione A
Anticancer Res; 2001; 21(2B):1395-9. PubMed ID: 11396221
[TBL] [Abstract][Full Text] [Related]
7. Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer.
Lumachi F; Ermani M; Marino F; Di Cristofaro L; Tombolan V; Brunello A; Roma A; Basso U
Anticancer Res; 2008; 28(1B):491-3. PubMed ID: 18383890
[TBL] [Abstract][Full Text] [Related]
8. Integrin expression and survival in human breast cancer.
Berry MG; Gui GP; Wells CA; Carpenter R
Eur J Surg Oncol; 2004 Jun; 30(5):484-9. PubMed ID: 15135474
[TBL] [Abstract][Full Text] [Related]
9. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.
Grönberg M; Fjällskog ML; Jirström K; Janson ET
Acta Oncol; 2012 Mar; 51(3):386-93. PubMed ID: 22067021
[TBL] [Abstract][Full Text] [Related]
10. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
11. E2F1 expression predicts outcome in Korean women who undergo surgery for breast carcinoma.
Kwon MJ; Nam ES; Cho SJ; Park HR; Shin HS; Park JH; Park CH; Lee WJ
Ann Surg Oncol; 2010 Feb; 17(2):564-71. PubMed ID: 19841979
[TBL] [Abstract][Full Text] [Related]
12. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta.
Papadaki I; Mylona E; Giannopoulou I; Markaki S; Keramopoulos A; Nakopoulou L
Histopathology; 2005 Jan; 46(1):37-42. PubMed ID: 15656884
[TBL] [Abstract][Full Text] [Related]
13. Alternative therapy for elderly patients with breast cancer.
von Rueden DG; Sessions SC
Am Surg; 1994 Jan; 60(1):72-8. PubMed ID: 8273979
[TBL] [Abstract][Full Text] [Related]
14. Utility of a simplified molecular classification of tumors for predicting survival of patients with invasive ductal breast carcinoma.
Muñoz-Díaz MM; Fernández-Aceñero MJ; Salvadores P; Schneider J
Anticancer Res; 2009 Nov; 29(11):4727-30. PubMed ID: 20032426
[TBL] [Abstract][Full Text] [Related]
15. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
[TBL] [Abstract][Full Text] [Related]
16. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
[TBL] [Abstract][Full Text] [Related]
17. Pure or mixed-type invasive lobular carcinoma?
Bulut N; Dede DS; Sari E; Altundag K
Hum Pathol; 2008 Jul; 39(7):1121; author reply 1121. PubMed ID: 18570979
[No Abstract] [Full Text] [Related]
18. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
19. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
Mehta RS
J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
[No Abstract] [Full Text] [Related]
20. Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.
Skowronek J; Piotrowski T
Neoplasma; 2002; 49(6):426-31. PubMed ID: 12584593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
